CIHL
MCID: HRN018
MIFTS: 10

Hearing Loss, Cisplatin-Induced (CIHL)

Categories: Ear diseases

Aliases & Classifications for Hearing Loss, Cisplatin-Induced

MalaCards integrated aliases for Hearing Loss, Cisplatin-Induced:

Name: Hearing Loss, Cisplatin-Induced 57
Hearing Loss, Cisplatin-Induced, Susceptibility to 57 29 13
Cihl 57

Classifications:



External Ids:

OMIM® 57 613290

Summaries for Hearing Loss, Cisplatin-Induced

OMIM® : 57 Cisplatin is a highly effective chemotherapeutic agent, but its use is restricted by the high incidence of irreversible ototoxicity associated with it. This ototoxicity causes serious permanent bilateral hearing loss in 10 to 25% of adults receiving the drug, and in up to 60% of children. The consequences of this ototoxicity are particularly serious in children, because even mild hearing loss can compromise language and cognitive development. Cisplatin ototoxicity frequently leads to dose reduction and premature termination of cisplatin treatment, which may affect overall survival rates (summary by Ross et al., 2009). (613290) (Updated 20-May-2021)

MalaCards based summary : Hearing Loss, Cisplatin-Induced, is also known as hearing loss, cisplatin-induced, susceptibility to. An important gene associated with Hearing Loss, Cisplatin-Induced is CIHL (Hearing Loss, Cisplatin-Induced, Susceptibility To). Affiliated tissues include eye.

Related Diseases for Hearing Loss, Cisplatin-Induced

Symptoms & Phenotypes for Hearing Loss, Cisplatin-Induced

Clinical features from OMIM®:

613290 (Updated 20-May-2021)

Drugs & Therapeutics for Hearing Loss, Cisplatin-Induced

Search Clinical Trials , NIH Clinical Center for Hearing Loss, Cisplatin-Induced

Genetic Tests for Hearing Loss, Cisplatin-Induced

Genetic tests related to Hearing Loss, Cisplatin-Induced:

# Genetic test Affiliating Genes
1 Hearing Loss, Cisplatin-Induced, Susceptibility to 29

Anatomical Context for Hearing Loss, Cisplatin-Induced

MalaCards organs/tissues related to Hearing Loss, Cisplatin-Induced:

40
Eye

Publications for Hearing Loss, Cisplatin-Induced

Articles related to Hearing Loss, Cisplatin-Induced:

# Title Authors PMID Year
1
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. 57
19898482 2009
2
Toll-like receptor 4 is activated by platinum and contributes to cisplatin-induced ototoxicity. 61
33733573 2021
3
Protective Effect of Tempol against Cisplatin-Induced Ototoxicity. 61
27869744 2016
4
[Cisplatin-induced hearing loss in children in relation to eye color]. 61
17180696 2007
5
[Reduced nutritional status enhances ototoxicity]. 61
8579670 1995

Variations for Hearing Loss, Cisplatin-Induced

Expression for Hearing Loss, Cisplatin-Induced

Search GEO for disease gene expression data for Hearing Loss, Cisplatin-Induced.

Pathways for Hearing Loss, Cisplatin-Induced

GO Terms for Hearing Loss, Cisplatin-Induced

Sources for Hearing Loss, Cisplatin-Induced

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....